skip to content

eLesor Investments version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 697.5 99.8" style="enable-background:new 0 0 697.5 99.8;" xml:space="preserve" aria-labelledby="title--mwlogoHeader desc--mwlogoHeader" role="img"> eLesor Site Logo A link that brings you back to the homepage.

eLesor Investments version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 200 42.5" style="enable-background:new 0 0 200 42.5;" xml:space="preserve" aria-labelledby="title--barronslogo desc--barronslogo" role="img">>

10 Beaten-Down Stocks That Could See a Rebound

Referenced Symbols

The Etsy website.

Dreamstime

Stocks have been rising in recent days, with the Dow Jones Industrial Average at its second-highest close on record on Monday, but not every company is hitting records.

Over the past few months, investors have pulled back from expensive growth stocks to favor cyclical ones, with many high-flying growth names taking a hit. As of the close on Friday, when the S&P 500 scored a record closing high, 30 stocks in the index had plunged at least 20% below their 52-week highs, with most of these in the technology, healthcare, and communication sectors. In the majority of cases, the stocks fell for a good reason: Their valuations surged so much that they no longer were justified by the stocks’ fundamentals.

This appears to be the case with ViacomCBS (ticker: VIAC) and Discovery (DISCA), both of which recently launched individual streaming services. Investors were excited by the media companies’ ambitious subscriber targets and other bright prospects—and shares of both companies were on a tear from March 2020 to March 2021.

However, as the stocks’ valuations got loftier and fewer investors were willing to keep chasing them, share prices plunged in late March of this year. Yet even after despite the recent drop, Viacom and Discovery shares are trading at higher valuations—relative to 12-month forward earnings—than they were a year ago, suggesting further room to fall.

Barron’s looked for the opposite: Beaten-down stocks whose valuations have now fallen below year-ago levels, which suggests a better chance for a rebound. We narrowed the screen by excluding companies whose 2022 earnings are expected to be lower than those for 2021—a potential red flag for stocks that are running ahead of themselves.

This left us with 10 names that are good candidates to buy on the low. 

Consider Etsy (ETSY): The online handicrafts marketplace soared 316% in the 12 months prior to its recent peak on March 1, as it saw a surge in both consumers and sellers during the pandemic lockdowns. The stock has lost one-third of those gains since March 2021, after the company pointed to solid, but less dramatic growth in the coming years. Wall Street estimates that Etsy will increase its earnings per share by 20% in fiscal year 2021 from a year ago, and then another 22% in fiscal year 2022.

Similarly, shares of chipmaker Advanced Micro Devices (AMD) have tumbled since peaking in January. In April, AMD increased its full-year guidance as a global shortage of semiconductors placed immense strain on the chip supply chain. The firm now forecasts revenue will grow roughly 50% compared with what it achieved in 2020, while earnings are expected to be 66% higher.

From a valuation perspective, both Etsy and AMD are more attractive now than they were a year ago. Penn National Gaming (PENN), Citrix Systems (CTXS), Vertex Pharmaceuticals (VRTX), MarketAxess (MKTX), Incyte (INCY), IPG Photonics (IPGP), Jack Henry & Associates (JKHY), and DexCom (DXCM) round out the stocks included in the screen.

Off the Peak

These stocks have plunged at least 20% below their 52-week highs, and now look cheaper compared to their past valuations.

Source: FactSet

Make no mistake, some of these stocks are still quite expensive in the traditional sense of valuation. They only look “cheap” as compared to their own past—which some might argue is a more relevant way to predict a stock’s future.

For example, shares of DexCom, which manufactures and sells continuous glucose monitoring systems for diabetes patients, are priced at 137 times their estimated earnings in the next 12 months. But investors today no longer only focus on a company’s one-year prospects. The stock is well-positioned to see exponential growth in the next five years as the tech for Dexcom’s products becomes more mainstream. Wall Street analysts are overwhelmingly bullish on Dexcom stock and have an average target price 30% higher than today’s level. 

Write to Evie Liu at [email protected]